Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria

• DOI: 10.1371/journal.pone.0205807
• Publication Date: 2018-10-18T17:40:25Z
• Authors: Ming-Chia Lee; Chen-Yuan Chiang; Chih-Hsin Lee; Cheng-Maw Ho; Chia-Hao Chang; Jann-Yuan Wang; Shih-Ming Chen
• Keywords: Contraindication

Human studies on the use of metformin as host-directed therapy (HDT) for tuberculosis (TB) are rare. We performed a nationwide cohort study to evaluate effect mitigating risk active TB among patients with diabetes mellitus (DM). Among newly diagnosed DM identified in Taiwan National Health Insurance Research Database, users, defined basis >90 cumulative daily doses within 1 year, and propensity-score-matched nonusers were selected. The primary outcome was incident TB, using diagnostic criteria validated by real patient data at medical center. Independent predictors investigated Cox regression analysis. Similar analysis subpopulation without history hypertensive nephropathy renal replacement therapy. A total 88,866 users Validation results showed that had sensitivity 99.13% specificity 99.90%. During follow-up, 707 807 developed TB. Metformin independently associated lower (hazard ratio [HR]: 0.84 [0.74-0.96]). high-dose than low-dose (HR: 0.83 [0.72-0.97]). remained when restricted function impairment. Newly diabetic contraindication should receive an anti-diabetic medication, potential additional benefit against